Although the EAU guidelines do not recommend PSMA‐PET/CT for primary staging but at least abdominopelvic CT and bone scanning for metastatic screening, the panel considered PSMA‐PET/CT the most appropriate imaging modality for the initial diagnosis of metastatic disease, and also more specifically of M1a disease in both de novo and recurrent setting. This evidence concerns the gene FOLH1 and metastatic neoplasm.